RELATIONSHIP BETWEEN ANTI-HYPERTENSIVE USE AND PARKINSON'S DISEASE RISK: A CROSS SECTIONAL STUDY.

JPUMHS;2023:13:04,117-121. http://doi.org/10.46536/jpumhs/2023/13.04.481

Abstract

ABSTRACT OBJECTIVE: to assessing the relationship between anti-hypertensive use and parkinson's disease risk. MATERIALS AND METHODS: The retrospective case-control study was conducted at the Chandka Medical College, Ladkana. A total of 326 participants were selected through a multi-stage stratified sampling method to ensure the sample represents the diversity of the target population. Participants aged 50-70 years with complete information on antihypertensive use, Parkinson’s disease diagnosis on Modified Hoehn (H) & Yahr (Y) stages. Participants with other diagnosed co-morbid were excluded from the study. Statistical results was analysed via SPSS version 22. RESULTS: The findings revealed no overall significant link between antihypertensive drug use and the risk of Parkinson’s disease (p>0.05). Subgroup analysis, on the other hand, revealed potential differences in risk profiles based on certain antihypertensive medication classes. Individuals on calcium channel blockers had a slightly increased risk of Parkinson’s disease (p=0.06), whereas those taking ACE inhibitors had a lower risk (p=0.08). These relationships were not statistically significant, but they merit additional study. CONCLUSION: According to the findings, antihypertensive drug use may not be a significant risk factor for Parkinson’s disease in the general population. Nonetheless, more research is needed into the potential differential effects of different antihypertensive medication classes on PD risk.